Early lactase enzyme supplementation: Efficacy to promote growth and feeding tolerance in preterm infants: A randomized controlled trial
Abstract
BACKGROUND: Transient lactase deficiency is common in preterm infants, which may contribute to feeding intolerance, poor growth, and adverse clinical outcomes. Early lactase enzyme supplementation can improve the clinical manifestations produced by lactose intolerance in preterm infants with better weight gain and rapid feeding increment.
AIM: To evaluate the efficacy and safety of lactase enzyme supplementation for improving feeding tolerance and promoting growth without adverse outcomes in Egyptian preterm infants.
METHODS: This prospective, randomized, double-blind, controlled trial included a total of 109 preterm infants born before 34 weeks’ gestation; 55 received lactase supplementation and 54 served as controls. Clinical signs of feeding intolerance, growth parameters, stool reducing substances, stool pH, laboratory findings, and other parameters such as hospital stay duration and patient outcome were assessed over 2 weeks.
RESULTS: The intervention group had lower gastric residuals at week 1 (P = 0.0002) and week 2 (P = 0.003), lower abdominal distension at week 1 (P = 0.007) and week 2 (P < 0.001), fewer emesis attacks at week 1 (P = 0.001), and a lower incidence of diarrhea at week 1 (P = 0.004) and week 2 (P = 0.002). Negative stool reducing substances were more frequent in the intervention group at week 1 (P = 0.011) and week 2 (P < 0.001), with significant in-group improvement only in the intervention arm (P < 0.001). Stool pH was higher in the intervention group at week 1 (P < 0.0001) and week 2 (P < 0.0001). Weight gain was greater (P < 0.0001), while necrotizing enterocolitis (NEC) was less frequently reported in the intervention group (P = 0.0448).
CONCLUSION: Lactase supplementation can improve feeding tolerance symptoms, stool pH, and daily weight gain, and may contribute to a reduction in NEC incidence in preterm infants.
Related
- Efficacy and safety of probiotic supplementation in PsA-a randomized controlled trial.
- Efficacy of yeast mannan supplementation on increasing stool frequency in adults: a randomized controlled trial
- Vitamin D screening and targeted supplementation delays liver fibrosis in patients with chronic liver disease: A prospective randomized controlled trial
- In randomized controlled trials with nutrient supplementation, participants with subjective memory complaints should not be combined with those having a mild cognitive impairment diagnosis
- Dose-dependent effects of sodium bicarbonate supplementation combined with sprint interval training on performance adaptations in basketball players: a randomized placebo-controlled trial
BibTeX
@article{morsi2026early,
title = {{Early lactase enzyme supplementation: Efficacy to promote growth and feeding tolerance in preterm infants: A randomized controlled trial}},
author = {Walaa E M A Morsi and Ayman E Eskander and Mohamed G Mostafa and Zahraa Ezz ElDin and Fatma A Abdel Maksoud and Amira Elrefaee},
journal = {World Journal of Clinical Pediatrics},
year = {2026},
month = nov,
doi = {10.5409/wjcp.124805},
url = {https://doi.org/10.5409/wjcp.124805},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - Early lactase enzyme supplementation: Efficacy to promote growth and feeding tolerance in preterm infants: A randomized controlled trial
AU - Walaa E M A Morsi
AU - Ayman E Eskander
AU - Mohamed G Mostafa
AU - Zahraa Ezz ElDin
AU - Fatma A Abdel Maksoud
AU - Amira Elrefaee
PY - 2026
DA - 2026/11/03
JO - World Journal of Clinical Pediatrics
DO - 10.5409/wjcp.124805
UR - https://doi.org/10.5409/wjcp.124805
AB - BACKGROUND: Transient lactase deficiency is common in preterm infants, which may contribute to feeding intolerance, poor growth, and adverse clinical outcomes. Early lactase enzyme supplementation can improve the clinical manifestations produced by lactose intolerance in preterm infants with better weight gain and rapid feeding increment. AIM: To evaluate the efficacy and safety of lactase enzyme supplementation for improving feeding tolerance and promoting growth without adverse outcomes in Egyptian preterm infants. METHODS: This prospective, randomized, double-blind, controlled trial included a total of 109 preterm infants born before 34 weeks’ gestation; 55 received lactase supplementation and 54 served as controls. Clinical signs of feeding intolerance, growth parameters, stool reducing substances, stool pH, laboratory findings, and other parameters such as hospital stay duration and patient outcome were assessed over 2 weeks. RESULTS: The intervention group had lower gastric residuals at week 1 (P = 0.0002) and week 2 (P = 0.003), lower abdominal distension at week 1 (P = 0.007) and week 2 (P < 0.001), fewer emesis attacks at week 1 (P = 0.001), and a lower incidence of diarrhea at week 1 (P = 0.004) and week 2 (P = 0.002). Negative stool reducing substances were more frequent in the intervention group at week 1 (P = 0.011) and week 2 (P < 0.001), with significant in-group improvement only in the intervention arm (P < 0.001). Stool pH was higher in the intervention group at week 1 (P < 0.0001) and week 2 (P < 0.0001). Weight gain was greater (P < 0.0001), while necrotizing enterocolitis (NEC) was less frequently reported in the intervention group (P = 0.0448). CONCLUSION: Lactase supplementation can improve feeding tolerance symptoms, stool pH, and daily weight gain, and may contribute to a reduction in NEC incidence in preterm infants.
SN - 2219-2808
ER -